Depressive Disorders and Incidence of COVID-19: Is There a Correlation and Management Interference?

Author Info

Nagwa Ali Sabri Mohamed Ahmed Raslan Eslam Mansour Shehata Sara Ahmed Raslan

Corresponding Author

Nagwa Ali Sabri
Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

A B S T R A C T

Corona virus Disease-2019 is a new strain of Coronaviruses (COVID-19) causing an infection which has rapidly spread all over the Globe, where the primary pathways of infection spreading reported to be through large respiratory droplets and the disease severity has varied from mild self-limiting flu like illness to acute pneumonia, respiratory collapse and death. On the other hand, depression is a disease that could be progress to a life-threatening condition that affects globally hundreds of millions of people. The aim of this review is desired to investigate and find a correlation between depressive disorders and the incidence of COVID19, where, pathogeneses of depressive disorder and its effect on the immunity system was addressed, besides the impact of depression on individual food intake and its complications regarding weight gain, insulin resistance, and immune system disruption was also discussed which by turn might increase the risk for infection with COVID-19. Finally, the possible drug-drug interactions between drugs included in management protocols of both depressive disorder including antidepressants and anxiolytics and COVID19 with possible proposed alternatives.

Article Info

Article Type

Review Article

Publication history

Received: Tue 01, Sep 2020
Accepted: Fri 11, Sep 2020
Published: Thu 24, Sep 2020

Copyright

© 2023 Nagwa Ali Sabri. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.PDR.2020.02.04